wsopvideo| Shanghai Pharmaceutical (02607.HK): I040 received clinical trial approval notice

Glonghui May 24 丨 Shanghai Pharmaceutical (601607)(02607wsopvideo.HK) AnnouncementwsopvideoRecently, Shanghai Pharmaceutical Group Co., Ltd.(hereinafter referred to as "Shanghai Pharmaceutical" or "Company") developedwsopvideoThe "I040"(hereinafter referred to as the "project") clinical trial application received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration (hereinafter referred to as the "State Food and Drug Administration").

I040 is a small molecule compound. Preclinical studies have shown that I040 can improve core symptoms in multiple animal models of depression and has better safety.

In August 2020, Shanghai Pharmaceutical signed a technology development agreement with Shanghai Dongxi Zhihui Biomedical Co., Ltd. for the product, according to which Shanghai Pharmaceutical owns full intellectual property rights, development and commercialization rights of the product. As of the disclosure date of this announcement, the project has invested a total of 4%.wsopvideo, RMB 4.5983 million.